| Literature DB >> 28052951 |
Faisal Inayat1, Hafeez Ul Hassan Virk2, Waqas Ullah3, Qulsoom Hussain4.
Abstract
Cannabinoid hyperemesis syndrome (CHS) is a rare clinical syndrome characterised by nausea, cyclic vomiting and severe abdominal pain in association with chronic cannabis use. It is often under-recognised or misdiagnosed, resulting in the unnecessary workup and frequent hospitalisations. Long-term treatment of CHS is abstinence from cannabis, but acute symptomatic management has been a struggle for many clinicians. The present report highlights the use of haloperidol as an agent that successfully and safely treats the unrelenting symptoms of CHS. 2017 BMJ Publishing Group Ltd.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28052951 PMCID: PMC5256592 DOI: 10.1136/bcr-2016-218239
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X